Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s489. https://doi.org/10.25251/skin.8.supp.489